Reproductive, Maternal, Newborn, and Child Health


Every year, 289,000 women die from child birth- or pregnancy-related causes, and 5.9 million children die from largely preventable causes, such as pneumonia and malaria. To end preventable child and maternal deaths, medicines and supplies must be available when and where they are needed without causing financial hardship. This requires a strong pharmaceutical system that ensures the availability of both appropriate medicines and service providers at service delivery points. The Millennium Development Goals (MDGs), which included a focus on decreasing maternal and child mortality, were generally successful. Globally, maternal mortality fell below 45%, and child mortality decreased by 53%. However, only 6 of the 75 project countries were on track to meet the goal of reducing maternal mortality; 25 were on track to meet the required child mortality reductions.

As the MDGs concluded in 2015, countries, donors, and partners launched the Sustainable Development Goals. These goals are more ambitious and comprehensive than the MDGs and require more focused, systems strengthening efforts. Maternal, newborn, and child health (MNCH) is part of the goal to ensure healthy lives, including “quality essential health care services and medicines and vaccines for all” by 2030.

The SIAPS Approach

SIAPS and its partners worked to improve women’s and children’s access to and use of life-saving medicines. Through a systems strengthening approach, SIAPS went beyond addressing supply chain challenges to incorporate interventions that benefit the whole system, including strengthening pharmaceutical legislation and policies and supporting community case management (CCM) and patient-centered care.

At a global level, SIAPS raised awareness of the barriers to essential maternal and child health commodities by participating on various technical reference teams for the United Nations Commission on Life-Saving Commodities for Women and Children (UNCoLSC), the Reproductive Health Supplies Coalition, and the Community Case Management Task Force, among others. At the country level, SIAPS worked to implement customizable tools and job aids, develop standard treatment guidelines, and streamline pharmaceutical management information systems for evidence-based decision making.


SIAPS supported the UNCoLSC with technical reference teams (TRTs). The supply chain TRT and SIAPS worked with other partners to develop both quantification guidance on UNCoLSC’s 13 life-saving reproductive, maternal, newborn, and child health commodities and reports on supply chain management best practices. SIAPS also supported the maternal health TRT to produce an inventory of tools to increase access to and improve the use of maternal health supplies and to develop a case study on integrating oxytocin in the vaccine cold chain in Mali. Through its support of the pneumonia and diarrhea working group, SIAPS validated job aids and dispensing envelopes in DRC and conducted a landscape analysis for treating newborn sepsis.

In addition, SIAPS developed innovative tools and resources to assist countries in ensuring access to MNCH commodities. These included methods to estimate the need for maternal health medicines to assist in quantification and procurement, tools to assess the subnational procurement of MNCH medicines, and a district-level guide to developing interventions that will improve the availability and use of medicines for childhood illness.

To assist countries in ending preventable child and maternal deaths, SIAPS supported a systems strengthening approach to addressing barriers to access. For example, SIAPS assisted the Ministries of Health in Guinea and Burundi in improving access to treatment for children under 5 years of age through CCM. In Burundi, SIAPS focused on maintaining the supply chain for community health workers and the quality of care provided; contributed to protocols, job aids, and other tools; and conducted an evaluation of CCM of malaria that included a costing study component.